These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 7269560)
21. Antithrombin and anti-Xa agents in the control of thrombogenesis. Fareed J; Shaikh T; Hoppensteadt DA Pharmazie; 2001 Oct; 56 Suppl 1():S12-21. PubMed ID: 11686086 [TBL] [Abstract][Full Text] [Related]
22. The current role of anticoagulants in cardiovascular medicine. De Caterina R J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):595-604. PubMed ID: 19571765 [TBL] [Abstract][Full Text] [Related]
24. [Intracardiac thrombosis and consecutive thromboembolisms in patients with heart valve diseases: predisposition and concepts for prevention]. Piper C; Horstkotte D Z Kardiol; 1998; 87 Suppl 4():1-6. PubMed ID: 9857461 [TBL] [Abstract][Full Text] [Related]
26. Thrombogenesis and anticoagulation in heart valve disease: towards a rational approach. Butchart EG J Heart Valve Dis; 1993 Jan; 2(1):1-6. PubMed ID: 8269101 [No Abstract] [Full Text] [Related]
27. [Biology and physiopathology of tissue factor and its relevance for cardiovascular diseases]. Del Turco S; De Caterina R Ital Heart J Suppl; 2003 Jul; 4(7):559-68. PubMed ID: 14558284 [TBL] [Abstract][Full Text] [Related]
28. [Antithrombotic and thrombolytic treatments: current concepts from the North American guidelines and French practice]. J Mal Vasc; 2005 Sep; 30 Spec No 2():2S8-2S79. PubMed ID: 16392541 [No Abstract] [Full Text] [Related]
30. [Risk factors of thrombotic complications in laparoscopic operations and their prevention]. Sedov VM; Salov AB Vestn Khir Im I I Grek; 2004; 163(3):11-3. PubMed ID: 15317153 [TBL] [Abstract][Full Text] [Related]
31. The impact of acute and chronic exercise on thrombosis in cardiovascular disease. Bacon SL; Pelletier R; Lavoie KL Thromb Haemost; 2009 Mar; 101(3):452-9. PubMed ID: 19277404 [TBL] [Abstract][Full Text] [Related]
34. [Prevention and treatment of thrombosis after implantation of drug-eluting stents]. Han YL Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1516-7. PubMed ID: 17785098 [No Abstract] [Full Text] [Related]
35. Thiazolidinediones may be effective in the prevention of stent thrombosis with DES. Cao Z; Zhou Y Med Hypotheses; 2008; 70(2):329-32. PubMed ID: 17644271 [TBL] [Abstract][Full Text] [Related]
36. The genetics of antiplatelet drug resistance. Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731 [TBL] [Abstract][Full Text] [Related]
38. [New concepts of anticoagulant therapy of atrial fibrillation]. Guedon-Moreau L; Brigadeau F; Kacet S Arch Mal Coeur Vaiss; 2004 Nov; 97(11):1058-62. PubMed ID: 15609907 [TBL] [Abstract][Full Text] [Related]
39. Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis. Haran MZ; Lichman I; Berebbi A; Weinmann E; Rosenberg N Br J Haematol; 2007 Oct; 139(2):310-1. PubMed ID: 17897308 [TBL] [Abstract][Full Text] [Related]
40. Anticoagulant agents are mainstay therapies in the prevention and treatment of arterial and venous thrombosis. Introduction. Nutescu EA Am J Manag Care; 2006 Dec; 12(16 Suppl):S427-9. PubMed ID: 17203986 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]